Hereditary papillary renal cell carcinoma
MONDO:0003789A familial carcinoma inherited in an autosomal dominant trait. It is characterized by the development of multiple, bilateral papillary renal cell carcinomas. The carcinomas range from microscopic lesions to clinically symptomatic tumors. It is associated with activating mutations of the MET oncogene.
Also known as: familial renal papillary carcinoma, hereditary kidney papillary carcinoma, hereditary papillary carcinoma of kidney, hereditary papillary carcinoma of the kidney, hereditary papillary renal carcinoma, hereditary papillary renal cell cancer, hereditary papillary renal cell carcinoma, renal cell carcinoma, papillary
2779 clinical trials for this condition and its sub-types, 2 tagged with Hereditary papillary renal cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. …
Phase 1 • Sponsor: DeuterOncology • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Scientists track families to unlock secrets of inherited kidney cancer
Knowledge-focused Recruiting nowThis study follows families with a history of inherited kidney cancer to learn more about the disease's genetic causes and how it progresses. Researchers will collect blood, tissue, and urine samples from affected individuals and their relatives. The goal is to identify new genes…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC